Physician

Jarrod B. Adkison, M.D.

According to 2025 Medicare claims, Jarrod Adkison, M.D. (NPI: 1790719318) practices radiation oncology in the Dothan, AL market, with the plurality of this provider's patient population coming from Houston, AL. This provider's primary affiliated billing organization is WIREGRASS RADIATION ONCOLOGY PC (NPI: 1871620484; TIN: 680558150) and primary practice location at 36301-3022. Adkison is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), participating under the MSSP model.

Adkison's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 353 traditional Medicare patients, billed 11,169 HCPCS/CPT codes, and received $614,883 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 2,226 prescription claims across 543 beneficiaries totaling $240,879 in drug costs, led by Orgovyx (Relugolix). 2023 DME data shows 33 claims. Open Payments data shows 33 records totaling $878. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $1,097,251 to $614,883. In contrast, Part D prescription costs have moved sharply higher in recent years, from $50,621 to $240,879. For DME billing, this smaller-volume category moved up and down with repeated peaks and valleys, starting at $3,506 and ending at $519.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	729	10,551	$1,097,251
2016	731	10,545	$1,088,549
2017	658	10,773	$982,393
2018	476	10,043	$576,534
2019	513	11,507	$669,231
2020	472	11,207	$696,063
2021	422	10,644	$656,248
2022	377	11,465	$688,407
2023	369	10,757	$616,253
2024	353	11,169	$614,883

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	324	1,591	$50,621
2016	348	1,705	$68,782
2017	354	1,734	$53,006
2018	366	1,788	$61,336
2019	399	1,828	$70,103
2020	415	1,638	$61,785
2021	440	1,811	$57,556
2022	428	1,749	$56,678
2023	486	2,033	$141,505
2024	543	2,226	$240,879

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	51	$3,443
2016	N/R	28	$1,683
2017	N/R	29	$1,270
2018	N/R	43	$3,921
2019	N/R	12	$2,245
2020	N/R	11	$2,093
2021	N/R	N/R	N/R
2022	N/R	11	$1,417
2023	N/R	33	$7,639
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	160	160	$136
77263	Complex radiation therapy planning	183	208	$125
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	206	298	$70
77334	Design and construction of complex radiation treatment device	186	2,189	$46
77300	Calculation of radiation therapy dose	184	3,282	$24

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Orgovyx	Relugolix	65	1,950	$173,748
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	21	630	$14,042
Tamsulosin Hcl	Tamsulosin Hcl	248	20,774	$4,387
Ondansetron Hcl	Ondansetron Hcl	137	3,786	$3,470
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	132	2,477	$2,915

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	33	$878	Sumitomo Pharma America, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jarrod B. Adkison, M.D.?

Tedicare shows public-source Medicare data for Jarrod B. Adkison, M.D. (NPI 1790719318), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jarrod B. Adkison, M.D. have ACO affiliation data?

Jarrod B. Adkison, M.D. is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604).

What billing organization is linked to Jarrod B. Adkison, M.D.?

Jarrod B. Adkison, M.D. is linked to WIREGRASS RADIATION ONCOLOGY PC (billing NPI 1871620484) in the available physician profile data.

Does Jarrod B. Adkison, M.D. have Open Payments data?

Jarrod B. Adkison, M.D. has 33 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.